Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
| Market Cap | $14.78B+27.3% |
| Revenue (ttm) | $4.72B+13.5% |
| Net Income | $205.95M+155.9% |
| EPS | $3.07+150.6% |
| Shares Out | 64.19M |
| PE Ratio | 64.32 |
| Forward PE | 8.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 984,697 |
| Open | $233.99 |
| Previous Close | $236.45 |
| Day's Range | $227.95 - $238.10 |
| 52-Week Range | $156.95 - $266.38 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | $295.73(+28.43%) |
| Earnings Date | Feb 23, 2027 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
9 firms rating JAZZ in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$JAZZ stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of JAZZ by members of U.S. Congress
| Thomas SuozziHouse / D | Sale$1.00K – $15.00K | Sep 26, 2022 |
| Thomas SuozziHouse / D | Purchase$1.00K – $15.00K | Oct 19, 2021 |
Recently reported changes in JAZZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by JAZZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
JAZZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
JAZZ Revenue by Segment or Geography
| Product sales, net | $1.20B | 42.99% |
| Sleep | $514.00M | 18.47% |
| Oncology | $387.10M | 13.91% |
| Epilepsy | $295.40M | 10.61% |
| Epidiolex/Epidyolex | $295.40M | 10.61% |
| All other | $48.60M | 1.75% |
| High-sodium oxybate AG royalty revenue | $38.40M | 1.38% |
| Other royalty and contract revenues | $8.10M | 0.29% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New JAZZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to JAZZ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in JAZZ
| IJHiShares Core S&P Mid-Cap ETF | $538.57M |
| VTIVanguard Morningstar Total Stock Market ETF | $333.06M |
| VBVanguard Morningstar Small-Cap ETF | $298.63M |
| AFTYPacer CSOP FTSE China A50 ETF | $270.47M |
| VBRVanguard Morningstar Small-Cap Value ETF | $194.10M |
| VFLOVictoryShares Free Cash Flow ETF | $172.07M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from JAZZ’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with valuation concerns offsetting some operational interest; mostly opinion pieces rather than concrete business news.
Recent Insider Activity
Insider Score Trend Over Time
-38.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| HMMJ.TO | Global X Marijuana Life Sciences Index ETF | 10.26% |
| HMLSF | Global X Marijuana Life Sciences Index ETF | 10.26% |
| BTAL | AGF U.S. Market Neutral Anti-Beta Fund | 3.72% |
| PINK | Simplify Health Care ETF | 3.63% |
| IHE | iShares U.S. Pharmaceuticals ETF | 3.26% |
| PJP | Invesco Pharmaceuticals ETF | 2.87% |
| TYNE | Direxion Nanotechnology ETF | 2.79% |
| MCOW | Pacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 2.75% |
| ASD | Defiance Autism Impact ETF | 2.66% |
| XMMO | Invesco S&P MidCap Momentum ETF | 2.57% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 2.57% |
| SILX | ETFMG Prime 2x Daily Junior Silver Miners ETF | 2.31% |
Weight is the stock’s share of each fund’s holdings.
